Building cell therapy ‘family,’ PE-backed Kiniciti takes stake in Ncardia

With the backing of a private equity firm and the conviction to invest in tools and services companies that can bring down costs of cell therapies and improve access to them, Kiniciti has taken a majority position in Belgium’s Ncardia as its first investment.

CEO Geoffrey Glass told BioCentury that Kiniciti Bio Inc. is targeting an area the firm believes isn’t adequately served by other investment firms: cell therapy tools and services companies that aren’t yet operating at a scale that generates enough cash flow to interest most buyers or PE firms, but that VCs might pass over in search of greater upside among therapeutics developers...